How Oncology Practices Are Adopting New Therapies
By Blood Cancers Today Staff Writers - Last Updated: February 27, 2025Lisa Herms, PhD, Associate Director at Ontada, discussed two key studies presented at the 66th American Society of Hematology Annual Meeting & Exposition. One study examined real-world use of bispecific antibodies in relapsed/refractory multiple myeloma, while the other analyzed patient characteristics and outcomes in diffuse large B-cell lymphoma before and after chimeric antigen receptor T-cell therapy approval. According to Herms, these findings offer valuable insights into evolving treatment strategies and clinical decision-making.
Advertisement
Advertisement
Related Posts
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The approval was based on the phase 3 IMerge study, which showed improved rates of transfusion independence with imetelstat.
A study finds shortened overall survival with thrombotic events more severe in arterial thrombosis than venous thrombosis.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Cema-cel is feasible and can induce durable responses in patients with LBCL, achieving an ORR of 58% and a CR rate of 42%.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.